[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Clatterbridge Cancer Centre NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100619262","breaking-barriers-to-research-access-100619262",false,"NCT07342335","Breaking Barriers to Research Access","Understanding and Breaking Barriers to Research Access for Cancer Patients","Inclusion Criteria:\n\n* Adults over 18 years. No upper age limit\n* A confirmed diagnosis of cancer\n* Patient planned to or is receiving treatment at The Clatterbridge Cancer Centre NHS Foundation Trust\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Patients with severe co-morbidities considered by the screening team to interfere with the individual's ability to complete requirements of the study or to provide informed consent.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","There is a need to improve accessibility to research and clinical trials within the NHS. Key groups are consistently under-represented in research: those from minority ethnic backgrounds, those with lower socio-economic status and those with impaired capacity. This leads to inequality of healthcare and an inequality of patient experience. Increasing access to research would not only broaden research opportunities and bridge gaps in health equality; diverse research representation means better understanding of disease mechanisms and greater generalisability of findings across the patient population. There are well described socio-economic issues across the region that this trust serves within Cheshire and Merseyside. This brings health challenges for patients. Clatterbridge Cancer Centre is a large networked cancer centre serving Cheshire and Merseyside using a hub model. Research is a core strategic theme; it is hugely important that it is understood not only the areas and hotspots of cancer across the region, but also that patients with those cancers can access a portfolio of research that serves a distinct patient need. Currently there is a lack of such triangulated information within the Trust, which may mean that patient need remains unmet. Therefore the research is designed to understand any barriers that patients may have in accessing research, in tandem with a demographic review and mapping of patient referral and access to the current trials portfolio. This will lead to a truly patient centred approach in accessing research.",[24],"Cancer",[26],"Research Barriers","RECRUITING","2026-04-13",{"date":30,"type":31},"2026-04-15","ACTUAL",{"date":33,"type":31},"2024-11-29",{"date":35,"type":20},"2026-11-30",{"name":37,"class":38},"The Clatterbridge Cancer Centre NHS Foundation Trust","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":39},"100618707","a-real-world-data-and-sample-compendium-of-frail-andor-multiply-treated-large-b-cell-lymphoma-100618707","NCT07335120","A Real-world Data and Sample Compendium of Frail and\u002For Multiply Treated Large B-cell Lymphoma","A reaL-world Data and Sample coMpendium of frAil aNd\u002For Multiply treAted Patients With Large B-Cell Lymphoma","ALMANAC","Inclusion Criteria:\n\n* Males and female subjects ≥16 years of age at the time of enrolment.\n* Ability to understand and sign written informed consent.\n* Previously untreated histologically proven Large B-cell non-Hodgkin's lymphoma (LBCL) according to the current World Health Organisation 2016 classification including all morphological variants.\n\nCohort A:\n\n* Large B-cell lymphomas i) Diffuse large B-cell lymphoma, NOS ii) T-cell\u002Fhistiocyte-rich large B-cell lymphoma iii) Diffuse large B-cell lymphoma\u002F high grade B-cell lymphoma with MYC and BCL2 re-arrangements. iv) High-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements v) ALK-positive large B-cell lymphoma vi) Large B-cell lymphoma with IRF4 rearrangement vii) High-grade B-cell lymphoma with 11q aberrations or Burkitt-like lymphoma with 11q aberration viii) EBV-positive diffuse large B-cell lymphoma EBV-positive diffuse large B-cell lymphoma, NOS ix) Diffuse large B-cell lymphoma associated with chronic inflammation x) Fibrin-associated large B-cell lymphoma xi) Plasmablastic lymphoma xii) Primary large B-cell lymphoma of immune-privileged sites (vitro-retinal and testis but not CNS) and Intravascular large B-cell lymphoma xiii) Primary mediastinal large B-cell lymphoma xiv) Mediastinal grey zone lymphoma B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma xv) High-grade B-cell lymphoma, NOS xvi) HIV or KSHV\u002FHHV8-positive diffuse large B-cell lymphoma\n* De novo presentations of transformed indolent B-cell lymphomas.\n* LBCL patients with de novo disease unfit for full dose R-CHOP\u002FPola-R-CHP OR\n\nCohort B:\n\n* LBCL patients (as in Cohort A) with relapsed\u002Frefractory disease (including de novo transformed indolent B-cell lymphomas) following frontline (one previous line of chemo-immunotherapy) including any line CAR-T therapy.\n* Patients fulfilling the above criteria who are on other trials\u002Fstudies are eligible for recruitment.\n* Patients previously registered into Cohort A with subsequent relapsed\u002Frefractory disease. Such patients can be registered into cohort B and will be given a new study number that is linked to their study number for cohort A.\n* Data for patients commencing treatment \\\u003C6 months prior to enrolment and with ongoing follow-up can be entered retrospectively.\n\nExclusion Criteria:\n\n1. Patients treated \\>6 months prior to trial enrolment (Cohort B).\n2. Patients eligible for full dose R-CHOP\u002FPola-R-CHP (Cohort A)\n3. Patients with CNS lymphoma\n4. Lymphoid proliferations and lymphomas associated with immune suppression and dysregulation. (e.g., Post-Transplant Lymphoproliferative Disorders)","17 Years",{"count":50,"type":20},800,"LBCL is a cancer of the lymphatic system where B-cells (a type of white blood cell) experience uncontrolled growth. The standard treatment for LBCL is a combination of chemotherapy and immunotherapy, referred to as chemo-immunotherapy. Currently, the best results in the treatment of LBCL is with a chemo-immunotherapy combination called R-CHOP or Pola-R-CHP. Full doses of treatment are not suitable for elderly or frail patients due to potential to cause side effects and heart problems. Such patients either receive a reduced dose called mini-R-CHOP or receive alternatives (e.g. R-GCVP or R-CEOP). Additionally, some patients treated with R-CHOP or Pola-R-CHP may not respond or may respond initially before relapsing. For these patients, treatment is not standardised, and practice varies between hospitals. ALMANAC aims to collect data about the management and outcomes of patients with LBCL who are unsuitable for standard treatments because they are not well enough to tolerate the side effects or because they have not responded or relapsed following initial treatment. In doing so, it will guide research into LBCL leading to a better understanding of this condition and better outcomes.",[53],"DLBCL","2026-01-05",{"date":56,"type":31},"2026-01-12",{"date":58,"type":31},"2024-10-30",{"date":60,"type":20},"2028-10-30",{"name":37,"class":38},""]